Posted by Michael Wonder on 12 Aug 2017
Institute for Clinical and Economic Review to evaluate comparative clinical effectiveness and value of emicizumab for haemophilia A
11 August 2017 - Open input period now open until 6 September 2017.
The Institute for Clinical and Economic Review will develop a report assessing the comparative clinical effectiveness and value of emicizumab (Genentech/Roche), a monoclonal antibody currently under review by the FDA for prevention of bleeding in patients who have haemophilia A with factor VIII inhibitors.
Factor VIII is the clotting protein that is deficient in haemophilia A, and inhibitors interfere with factor replacement therapy.
An FDA approval decision is expected in the first quarter of 2018.
